In a market that is fiercely devaluing companies and following a deflating non-approvable letter from the FDA for Risperdal, Alkermes Inc. said after the markets closed it and Reliant Pharmaceuticals LLC are nixing their planned merger that was valued at $934 million when it was announced in March. (BioWorld Today) Read More
